Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
To learn about the effectiveness of adding talazoparib to the standard of care treatment
combination of androgen ablation therapy (hormone therapy, also known as ADT) and
enzalutamide in patients with prostate cancer that has spread into the lymph nodes.